Berlin, March 26, 2013 – MOLOGEN AG is pleased to announce the appointment of Dr. Alfredo Zurlo as member of the executive board and Chief Medical Officer. As of April 1st, 2013 Dr. Zurlo, a board-certified oncologist with strong expertise in the pharma industry, will shape the company's clinical development programs, provide strategic input, and supervise all current and upcoming clinical trials of MOLOGEN. He has 13 years of extensive experience in clinical drug development, medical strategy, clinical trial design for both pre and post approval studies and in regulatory affairs.
“We are glad to have Alfredo join our company. With his outstanding expertise in drug development and clinical trials he will be of great value for the further development of the company and the expansion of our product pipeline. Especially for our lead cancer compounds MGN1703 and MGN1601 he will push forward the upcoming clinical trials and support our licensing talks with pharma companies” said Dr. Mathias P. Schlichting, chairman of the supervisory board of MOLOGEN AG.
Dr. Alfredo Zurlo stated: “The company has highly innovative cancer drugs in its pipeline which showed very impressive clinical data. In addition, their proprietary DNA vaccines are ready to enter clinical development. I am looking forward to joining a highly dedicated and competent management team. I will enjoy adding my expertise to get these exciting compounds into the market and to make a difference in patients’ life.”
Dr. Zurlo is currently working as Senior Medical Expert for the pharmaceutical and biotech industry and yet already advising MOLOGEN AG. He held numerous positions at Roche group between 2003 and 2011, including Medical Director Oncology and Senior International Medical Leader. At Roche he was responsible for medical affairs activities for the launch of Avastin® in metastatic colorectal cancer outside the US. From 1999 to 2003, prior to joining the industry, he was Medical Advisor at the European Organisation for Research and Treatment of Cancer (EORTC) in Brussels. Dr. Zurlo is board certified in Clinical Oncology and Radiation Therapy and has obtained his medical education at the University of Rome, where he served as University Research Associate and Lecturer from 1994 to 1998.
About MOLOGEN AG
MOLOGEN AG, a German biopharmaceutical company with headquarters in Berlin specializes in the research and development of innovative medications on the basis of DNA structures. The activities focus on numerous product developments which are relevant to the immune system; on the one hand vaccines against infectious diseases and on the other hand cancer medications. MOLOGEN AG is globally one of the few biotechnology companies with well tolerated DNA-based cancer treatment in the clinical development phase.
The stocks of MOLOGEN AG are listed in the Prime Standard of the German stock exchange (ISIN DE0006637200).
Memberships in associations:
Biotechnologieverbund Berlin-Brandenburg (bbb) e.V. | BIO Deutschland e.V. | DECHEMA - Society for chemical technology and biotechnology e.V. | German industrial association of biotechnology (DIB) | Association for the Promotion of Science and Humanities in Germany | Association of German biotechnology companies (VBU) | Association of researching manufacturers of pharmaceuticals e.V. (VFA) | Association of the chemical industry e.V. (VCI)
MIDGE®, dSLIM® and MOLOGEN® are registered trademarks of MOLOGEN AG.
Prof. Peter W. Huebner
Head of Corporate Communications
Tel: +49 - 30 - 84 17 88 - 38
Fax: +49 - 30 - 84 17 88 - 50
Tel: +49 - 30 - 84 17 88 - 13
Fax: +49 - 30 - 84 17 88 - 50
External Investor Relations
Kirchhoff Consult AG
Tel: +49 - 40 - 60 91 86 - 18
Fax: +49 - 40 - 60 91 86 -16
Note about risk for future predictions
Certain information in this report contains forward-looking statements or the corresponding statements with negation or versions deviating from this or comparable terminology. These are described as forward-looking statements. In addition, all of the information given here that refers to planned or future results of business areas, key financial figures, developments of the financial situation or other financial figures or statistical data, is to be understood as such forward-looking statements. The company points out to investors that they should not rely on these forward-looking statements as predictions about actual future events. The company is not obligated and refuses to accept any liability for the forward-looking statements and has no obligation to update such statements in order to accurately reflect the current situation.